04.26.10
ChromaDex Corporation, Irvine, CA, has launched pTeroPure (pterostilbene),
which is based on the grant of an exclusive worldwide license to all patent rights of pterostilbene from the University of Mississippi and the Agricultural Research Service—the principle intramural scientific agency of the USDA. The term of the license is up to and including the expiration of various pterostilbene patents held by the licensors. As a result of the licensing agreement, ChromaDex plans to pursue clinical studies and commercialization of its new product.
“pTeroPure Pterostilbene has the potential to be one of the most significant, new ingredients the dietary supplement industry has seen in a long time,” said Frank Jaksch, ChromaDex CEO. “Most people may not yet know of pterostilbene, but we, and others, believe this naturally occurring compound’s improved activity and potency may soon make it as well known as its highly-successful, well known relative, resveratrol.”
In related news, The Frost Group, LLC, led by Miami entrepreneur and billionaire Dr. Phillip Frost, has agreed to make an investment in ChromaDex. The amount of the investment was not disclosed. The investment will allow ChromaDex to pursue clinical studies and commercialization for its new pTeroPure pterostilbene, as well as to continue development of several other novel natural ingredients. ChromaDex separately announced today its has entered into an exclusive worldwide license with the University of Mississippi and the USDA Agricultural Research Service for all patent rights of pterostilbene.
Commenting on the announcement, Dr. Frost, stated, “It is with enthusiasm that we make this investment in ChromaDex. The company has a solid reputation and an experienced management team with considerable expertise in identifying and developing innovative and novel phytochemical ingredients. Moreover, we are impressed with the prospects for the company's product and IP portfolio, including pterostilbene, a unique compound that has considerable market potential.”
which is based on the grant of an exclusive worldwide license to all patent rights of pterostilbene from the University of Mississippi and the Agricultural Research Service—the principle intramural scientific agency of the USDA. The term of the license is up to and including the expiration of various pterostilbene patents held by the licensors. As a result of the licensing agreement, ChromaDex plans to pursue clinical studies and commercialization of its new product.
“pTeroPure Pterostilbene has the potential to be one of the most significant, new ingredients the dietary supplement industry has seen in a long time,” said Frank Jaksch, ChromaDex CEO. “Most people may not yet know of pterostilbene, but we, and others, believe this naturally occurring compound’s improved activity and potency may soon make it as well known as its highly-successful, well known relative, resveratrol.”
In related news, The Frost Group, LLC, led by Miami entrepreneur and billionaire Dr. Phillip Frost, has agreed to make an investment in ChromaDex. The amount of the investment was not disclosed. The investment will allow ChromaDex to pursue clinical studies and commercialization for its new pTeroPure pterostilbene, as well as to continue development of several other novel natural ingredients. ChromaDex separately announced today its has entered into an exclusive worldwide license with the University of Mississippi and the USDA Agricultural Research Service for all patent rights of pterostilbene.
Commenting on the announcement, Dr. Frost, stated, “It is with enthusiasm that we make this investment in ChromaDex. The company has a solid reputation and an experienced management team with considerable expertise in identifying and developing innovative and novel phytochemical ingredients. Moreover, we are impressed with the prospects for the company's product and IP portfolio, including pterostilbene, a unique compound that has considerable market potential.”
